*Acid control (pH >4) does not imply symptom relief. The correlation of pH data to clinical outcome has not been directly established.
†Prilosec OTC contains the active ingreadient omeprazole magnesium 20.6 mg, equivalent to omeprazole 20 mg used in this study.
‡Managed Markets Insight & Technology, LLC, database as of April 2016.
§Based on patients completing an overall treatment effect (OTE) questionnaire at week 2 to report if their upper abdominal pain and/or discomfort was improving or worsening using a 7-grade scale. For analysis, the OTE questionnaire was combined into a 15-point scale comprising the 7-point improvement scale, the status “about the same,” and the 7-point worsening scale.
Brands are trademarks of their respective owners.
References: 1. Lind T, Rydberg L, Kylebäck A, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2000;14(7):861-867. 2. Katz P, Kahrilas PJ, Johnson DA, et al. Daytime intragastric acid control: post hoc analyses of esomeprazole 20 mg and over-the-counter proton-pump inhibitors. Therap Adv Gastroenterol. 2015;8(6):322-330. 3. Wilder-Smith C, Lind T, Lundin C, Nauclér E, Nilsson-Pieschl C, Röhss K. Acid control with esomeprazole and lansoprazole: a comparative dose-response study. Scand J Gastroenterol. 2007;42(2):157-164. 4. Katz PO, Le Moigne A, Pollack C. Analysis of 2-week data from two randomized, controlled trials conducted in subjects with frequent heartburn treated with esomeprazole 20 mg. Clin Ther. 2017;39(5):960-970. 5. Data on file. Pfizer, Inc. New York, NY, 2015.